NEW YORK (GenomeWeb News) – Clinical Data today said that it has started a collaboration with the University of Pittsburgh to discover and validate genetic variants that could predict response to certain cancer treatments.

The partners will focus on variants in the Fc gamma receptor genes, which they believe could potentially predict patient response to monoclonal antibody therapies, such as cetuximab (Erbitux) and trastuzumab (Herceptin), and other monoclonal antibodies of the IgG1 subclass for treating cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.